Industry News
Share your love
Santen, Arctic Vision to Launch ARVN001 in China
Clearside Biomedical has announced that Arctic Vision, its Asia-Pacific partner, has signed a commercial collaboration agreement with Santen Pharmaceutical Co. for ARVN001 (known in the United States as XIPERE) to treat uveitic macular edema (UME) and additional ophthalmic indications in…
FDA Approves LumiThera’s Valeda for Dry AMD Treatment
The U.S. FDA has granted LumiThera authorization to market its Valeda Light Delivery System, the first FDA-authorized device designed to treat vision loss in patients with dry age-related macular degeneration (AMD). This significant approval, obtained through the De Novo authorization…
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials
The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD). This milestone makes HG202 the first CRISPR/Cas13Y RNA-targeting therapy in clinical development and the…
VSY Biotechnology Unveils Maestro® Sinusoidal IOL at ESCRS24
VSY Biotechnology to Complete Global Rollout of its Sinusoidal Vision Technology (SVT®) at ESCRS 2024 This year’s European Society of Cataract and Refractive Surgeons (ESCRS) 2024 kicked off with the highly anticipated third iNovation Day, which brought together the medical…
BlueRock Therapeutics’ OpCT-001 Receives FDA Clearance
BlueRock Therapeutics, a subsidiary of Bayer, announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to initiate a phase 1/2a clinical…
$6.4M Grant for New Dry AMD & Stargardt Treatments
Dr. Christopher Cioffi, the Thomas and Constance D’Ambra Professor in Organic Chemistry at Rensselaer Polytechnic Institute, is collaborating with Dr. Konstantin Petrukhin, Professor of Ophthalmic Science at Columbia University, to develop promising compounds aimed at treating dry age-related macular degeneration…
MD Student Presents at American Academy of Ophthalmology Conference – Elson S. Floyd College of Medicine
MD Student Presents at American Academy of Ophthalmology Conference Elson S. Floyd College of Medicine Source: Author: | Date: 2024-10-28 07:00:00 Source: Author: | Date: 2024-10-28 07:00:00
Promising Drug for Preventing Diabetic Eye and Kidney Disease
New research led by the University of Bristol has identified a promising type of inhibitor drug that could potentially prevent microvascular diabetic complications, including diabetic eye and kidney disease. The study, published in Cardiovascular Diabetology, focuses on protecting the glycocalyx,…
Aviceda’ Kicks off Phase II/III SIGLEC Trial for AMD
Aviceda Therapeutics has initiated the second part of its Phase II/III SIGLEC trial for AVD-104, an ophthalmic candidate aimed at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company has dosed the first subject in this phase,…
CDC Investigates Multistate Outbreak Related to Artificial Tears
A recent investigation led by the Centers for Disease Control and Prevention (CDC) has shed light on a multistate outbreak of carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa, linked to the use of artificial tears. The details of the investigation were published in…